Mepolizumab intravenous (IV) vs placebo
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
- no estimate extracted2 studies · 369 participantsHigh
Findings
What do systematic reviews say?
7 questions · 7 findings · 1 reviews
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 7 · 100%
Mepolizumab intravenous (IV) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted2 studies · 369 participantsHigh
Mepolizumab intravenous (IV) vs placebo
FEV1 · people with asthma
1 finding from 1 review
- no estimate extracted2 studies · 690 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Serious adverse events · people with asthma
Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.59 [0.37, 0.94]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.72 [0.18, 2.92]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.53 [0.44, 0.64]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Rate of exacerbations requiring emergency department treatment or admission · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.52 [0.31, 0.87]2 studies · 690 participantsHigh